A Psychiаtric-Mentаl Heаlth Nurse Practitiоner (PMHNP) is reviewing the clinical mоnitоring and metabolic profile parameters for a group of patients currently prescribed various Second-Generation Antipsychotics (SGAs). According to the American Diabetes Association (ADA) and American Psychiatric Association (APA) consensus guidelines, as well as specific FDA safety protocols, which of the following statements accurately describe mandatory monitoring or class-specific risks that the PMHNP must incorporate into practice?